REGENXBIO Inc.
RGNX$403M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaROCKVILLE
Clinical-stage biotechnology company developing AAV gene therapies
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
5
Next Catalyst
Aug 6, 2026
4wMarket Overview
Stock performance and key metrics
RGNX News
Catalyst Timeline
5 upcoming, 0 past
How RGNX's past catalysts played out
Drug Pipeline
No drugs found in this phase.
📑
→Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
Catalyst Verdict
Full breakdown — the signals behind the verdict
Market-Implied Move
Regulatory Approvals
Frequently asked questions
When is REGENXBIO Inc.'s next FDA catalyst?→
REGENXBIO Inc.'s (RGNX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RGNX biotech catalysts?→
Add RGNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow REGENXBIO Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply